In a bid to curb unethical practices within the pharmaceutical industry, the Department of Pharmaceuticals has rolled out the Uniform Code for Pharmaceutical Marketing Practices 2024 (UCPMP 2024). This move, aimed at fostering ethical marketing standards, marks a significant step in regulating the sector. Union Secretary, Arunish Chawla, recently disclosed to ThePrint that while the code operates on a self-regulatory basis, an ethics panel will diligently oversee its implementation.
Vigilance Against Unethical Practices
Chawla underscored the importance of the newly formed ethics committee, comprising members from various pharma associations, in ensuring compliance with the UCPMP 2024. Notably, a special auditor panel will be tasked with conducting thorough checks when necessary, emphasizing the commitment to maintaining ethical standards in the industry.
Addressing Concerns and Enhancing Accessibility
Responding to concerns regarding the availability of commonly used drugs, Chawla outlined measures to enhance accessibility. Initiatives include leveraging mobile applications to track drug availability and expanding the reach of Janasudhi Kendras through women self-help groups. These efforts aim to establish 25,000 centers in the near future, providing affordable and quality drugs to the masses.
Future Priorities: Building a Stronger Healthcare Ecosystem
Looking ahead, Chawla outlined the government’s priorities for the next five years, with a focus on strengthening the healthcare ecosystem. Key objectives include establishing a robust value chain for vaccines and biological molecules, positioning India as a leading manufacturer of medical devices, and promoting indigenous production through schemes like the Production Linked Incentive (PLI).
Towards Self-Reliance in Healthcare Manufacturing
Highlighting India’s growing prominence in the global healthcare landscape, Chawla emphasized the country’s potential to emerge as a pharmaceutical powerhouse. With a burgeoning export market and significant strides in medical device manufacturing, India is poised to lead the way in supplying quality drugs and healthcare products worldwide.
Bridging the Skills Gap
Addressing the challenge of skilled manpower, Chawla highlighted the importance of investing in professional training programs. Initiatives such as courses in M.Pharma and M.Tech aim to equip individuals with the necessary skills to meet the industry’s evolving demands, ensuring a steady supply of qualified professionals.
As India charts its course towards self-reliance and excellence in pharmaceuticals and healthcare manufacturing, concerted efforts towards ethical practices, accessibility, and skill development will play pivotal roles in shaping the industry’s trajectory.
